A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms.
Wafa Ben HamoudaMariem HanachiSonia Ben HamoudaWafa Kammoun RebaiAdel GharbiAmor BaccoucheJihene BettaiebOussema SouiaiMohamed Ridha BarboucheKoussay DellagiMelika Ben AhmedChaouki BenabdessalemPublished in: Tropical medicine and infectious disease (2024)
After following up for 12 months post-immunization, we concluded that the hierarchy between the platforms for anti-RBD antibody-titer dynamics was RNA vaccines, followed by viral-vector and alum-adjuvanted inactivated vaccines.